Publications
5491 Results
- Journal / Conference
- ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster;J Clin Oncol 42, 2024 (suppl 16; abstr 2655)
- Year
- 2024
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- Study Number(s)
- S1609
Correlations Between First Cycle Toxicity and Overall Survival in Patients with Rare Cancers Treated with Immune Checkpoint Inhibitors (NCI/SWOG S1609)
- Journal / Conference
- ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster;J Clin Oncol 42, 2024 (suppl 16; abstr 5081)
- Year
- 2024
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1216
Correlation of Body Mass Index (BMI) with survival outcomes in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Analysis of Patient (pt) Level Data from SWOG 1216 study
- Journal / Conference
- ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), TIP, poster; J Clin Oncol 42, 2024 (suppl 16; abstr TPS8657)
- Year
- 2024
- Research Committee(s)
- Lung
- Study Number(s)
- S2302
SWOG S2302, PRAGMATICA - LUNG: A Prospective Randomized Study of Ramucirumab plus Pembrolizumab (PR) versus Standard of Care (SOC) for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer
- Journal / Conference
- ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), TIPS, poster; J Clin Oncol 42, 2024 (suppl 16; abstr TPS4201)
- Year
- 2024
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- Study Number(s)
- S2012
SWOG S2012: Randomized Phase II/III Trial of First Line Platinum (P) / Etoposide (E) with or without Atezolizumab (NSC #783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)
- Journal / Conference
- ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster; J Clin Oncol 42, 2024 (suppl 16; abstr TPS4617)
- Year
- 2024
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1937
A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937- Updated Design
- Journal / Conference
- ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster; J Clin Oncol 42, 2024 (suppl 16; abstr 9564)
- Year
- 2024
- Research Committee(s)
- Melanoma
- Study Number(s)
- S1404
Association between Postoperative Circulating Tumor DNA (ctDNA) and Recurrence-Free Survival (RFS) in Patients with Resected Stage III Melanoma - an Exploratory Analysis of SWOG S1404
- Journal / Conference
- ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster;J Clin Oncol 42, 2024 (suppl 16; abstr 6529)
- Year
- 2024
- Research Committee(s)
- Leukemia
- Study Number(s)
- S1203
Treatment discontinuation due to toxicity for patients with acute myeloid leukemia (AML) treated on SWOG S1203
- Journal / Conference
- ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster;J Clin Oncol 42, 2024 (suppl 16; abstr 2619)
- Year
- 2024
- Research Committee(s)
- Lung
- Study Number(s)
- S1800D
Lung-MAP S1800D: A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy
- Journal / Conference
- ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), oral; J Clin Oncol 42, 2024 (suppl 16; abstr 12005)
- Year
- 2024
- Research Committee(s)
- Symptom Control and Quality of Life
- Study Number(s)
- S1714
Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Patients with Early-Stage Cancer Receiving Taxane Therapy: SWOG S1714 (NCT# 03939481)
- Journal / Conference
- ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), oral presentation; J Clin Oncol 42, 2024 (suppl 16; abstr 505)
- Year
- 2024
- Research Committee(s)
- Breast
- Study Number(s)
- S1007